NASDAQ:XBIO - Xenetic Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 112.77 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.35
▲ +0.01 (0.43%)

This chart shows the closing price for XBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Xenetic Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XBIO

Analyst Price Target is $5.00
▲ +112.77% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Xenetic Biosciences in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 112.77% upside from the last price of $2.35.

This chart shows the closing price for XBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Xenetic Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2021HC WainwrightBoost Price TargetBuy$2.00 ➝ $5.00High
8/14/2020Maxim GroupInitiated CoverageBuy$2.50High
8/13/2020HC WainwrightReiterated RatingBuy$2.00Medium
6/17/2020HC WainwrightReiterated RatingBuy$2.00Low
5/4/2020HC WainwrightInitiated CoverageBuyLow
1/8/2020Maxim GroupInitiated CoverageBuy$2.50High
12/20/2016LADENBURG THALM/SH SHInitiated CoverageBuy$10.00N/A
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 5 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/21/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2021

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Xenetic Biosciences logo
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Read More

Today's Range

Now: $2.35
Low: $2.17
High: $2.37

50 Day Range

MA: $2.92
Low: $1.73
High: $5.30

52 Week Range

Now: $2.35
Low: $0.76
High: $5.85

Volume

488,700 shs

Average Volume

3,856,140 shs

Market Capitalization

$22.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Xenetic Biosciences?

The following Wall Street analysts have issued reports on Xenetic Biosciences in the last year: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for XBIO.

What is the current price target for Xenetic Biosciences?

1 Wall Street analysts have set twelve-month price targets for Xenetic Biosciences in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 112.8%. HC Wainwright has the highest price target set, predicting XBIO will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for Xenetic Biosciences in the next year.
View the latest price targets for XBIO.

What is the current consensus analyst rating for Xenetic Biosciences?

Xenetic Biosciences currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XBIO will outperform the market and that investors should add to their positions of Xenetic Biosciences.
View the latest ratings for XBIO.

What other companies compete with Xenetic Biosciences?

How do I contact Xenetic Biosciences' investor relations team?

Xenetic Biosciences' physical mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The company's listed phone number is 781-778-7720 and its investor relations email address is [email protected] The official website for Xenetic Biosciences is www.xeneticbio.com.